Association of antihypertensive drugs with psoriasis: A trans-ancestry and drug-target Mendelian randomization study
Vascul Pharmacol. 2024 Feb 13:107284. doi: 10.1016/j.vph.2024.107284. Online ahead of print.NO ABSTRACTPMID:38360195 | DOI:10.1016/j.vph.2024.107284 (Source: Vascular Pharmacology)
Source: Vascular Pharmacology - February 15, 2024 Category: Drugs & Pharmacology Authors: Xiao Xu Shu-Yun Wang Rongyun Wang Lin-Yun Wu Min Yan Zhi-Ling Sun Qiu-Hua Sun Source Type: research
Immune response following transcatheter aortic valve procedure
Vascul Pharmacol. 2024 Feb 9;154:107283. doi: 10.1016/j.vph.2024.107283. Online ahead of print.ABSTRACTAortic valve stenosis is the most common type of heart valve disease in the United States and Europe and calcific aortic stenosis (AS) affects 2-7% of people aged 65 years and older. Aortic valve replacement (AVR) is the only effective treatment for individuals with this condition. Transcatheter Aortic Valve Replacement (TAVR) has been widely accepted as a minimally invasive therapeutic approach for addressing symptomatic AS in patients who are considered to have a high risk for traditional surgical intervention. TAVR pro...
Source: Vascular Pharmacology - February 10, 2024 Category: Drugs & Pharmacology Authors: Kasra Talebi Anaraki Zahra Zahed Roozbeh Narimani Javid Sasan Shafiei Fereshteh Beiranvandi Negin Ghasemi Kahrizsangi Faraz Golafshan Alireza Arzhangzade Javad Kojuri Samin Almassian Raha Hadi Pourya Gholizadeh Fahimeh Kazeminava Source Type: research
Effect of reactive oxygen, nitrogen, and sulfur species on signaling pathways in atherosclerosis
Vascul Pharmacol. 2024 Feb 5;154:107282. doi: 10.1016/j.vph.2024.107282. Online ahead of print.ABSTRACTAtherosclerosis is a chronic inflammatory disease in which fats, lipids, cholesterol, calcium, proliferating smooth muscle cells, and immune cells accumulate in the intima of the large arteries, forming atherosclerotic plaques. A complex interplay of various vascular and immune cells takes place during the initiation and progression of atherosclerosis. Multiple reports indicate that tight control of reactive oxygen species (ROS), reactive nitrogen species (RNS), and reactive sulfur species (RSS) production is critical for...
Source: Vascular Pharmacology - February 7, 2024 Category: Drugs & Pharmacology Authors: Kundan Solanki Evgeny Bezsonov Alexander Orekhov Suraj P Parihar Shivani Vaja Fletcher A White Alexander G Obukhov Mirza S Baig Source Type: research
Adiponectin secretion by perivascular adipose tissue supports impaired vasodilation in a mouse model of accelerated vascular smooth muscle cell and adipose tissue aging
CONCLUSIONS: PVAT-derived adiponectin is able to partially compensate for age-related decline in NO-mediated vasodilation, even during strong lipodystrophy, in conditions of absence of compensating EDH. In aorta with healthy PVAT acetylcholinesterase modulates vascular tone, but this is lost during aging, further compensating for decreased acetylcholine responsiveness. Thus, preservation of adiponectin levels, through relatively increased production in lipodystrophic PVAT, and reduction of cholinesterase might be regulatory mechanisms of the PVAT to preserve cholinergic vasodilation during aging.PMID:38320678 | DOI:10.1016...
Source: Vascular Pharmacology - February 6, 2024 Category: Drugs & Pharmacology Authors: A A J üttner E Ataei Ataabadi K Golshiri R de Vries I M Garrelds A H J Danser J A Visser A J M Roks Source Type: research
Comparative effectiveness of oral therapies targeting the prostacyclin pathway in pulmonary arterial hypertension: A systematic review and network meta-analysis
CONCLUSIONS: No differences in 6MWD change, clinical worsening reduction and adverse events rates were found among oral treprostinil and selexipag, resulting in similar efficacy and safety profiles.PMID:38309551 | DOI:10.1016/j.vph.2024.107280 (Source: Vascular Pharmacology)
Source: Vascular Pharmacology - February 3, 2024 Category: Drugs & Pharmacology Authors: Giovanna Manzi Marco Valerio Mariani Domenico Filomena Tommaso Recchioni Silvia Papa Gianmarco Scoccia Roberto Badagliacca Carmine Dario Vizza Source Type: research
Doxycycline induces mitochondrial dysfunction in aortic smooth muscle cells
Vascul Pharmacol. 2024 Jan 23;154:107279. doi: 10.1016/j.vph.2024.107279. Online ahead of print.ABSTRACTThe antibiotic doxycycline is known to inhibit inflammation and was therefore considered as a therapeutic to prevent abdominal aortic aneurysm (AAA) growth. Yet mitochondrial dysfunction is a key-characteristic of clinical AAA disease. We hypothesize that doxycycline impairs mitochondrial function in the aorta and aortic smooth muscle cells (SMCs). Doxycycline induced mitonuclear imbalance, reduced proliferation and diminished expression of typical contractile smooth muscle cell (SMC) proteins. To understand the underlyi...
Source: Vascular Pharmacology - January 25, 2024 Category: Drugs & Pharmacology Authors: Carmen Yap Shaynah Wanga Rob C I W üst Bram W van Os Maud M E Pijls Sofie Keijzer Eva van Zanten David R Koolbergen Antoine H G Driessen Ron Balm Kak Khee Yeung Carlie J M de Vries Riekelt H Houtkooper Jan H N Lindeman Vivian de Waard Source Type: research
COVID-19 plasma induces subcellular remodelling within the pulmonary microvascular endothelium
CONCLUSION AND IMPACT: During COVID-19, the pMV undergoes significant remodelling, which is evident based on the functional, phenotypic, and transcriptional changes seen following exposure to COVID-19 plasma. The observed morphological variation may be responsible for downstream complications, such as a decline in overall cellular function and cell-to-cell barrier integrity. Moreover, genes identified through bulk RNA sequencing may contribute to our understanding of the observed phenotype and assist in developing strategies that can inform the rescue of the dysregulated endothelium.PMID:38266794 | DOI:10.1016/j.vph.2024.1...
Source: Vascular Pharmacology - January 24, 2024 Category: Drugs & Pharmacology Authors: Rainha Passi Justyna Cholewa-Waclaw Ryan Wereski Matthew Bennett Stefan Veizades Bronwyn Berkeley Andrea Caporali Ziwen Li Julie Rodor Mieke Dewerchin Nicholas L Mills Abdelaziz Beqqali Mairi Brittan Andrew H Baker Source Type: research
The perspective of cAMP/cGMP signaling and cyclic nucleotide phosphodiesterases in aortic aneurysm and dissection
Vascul Pharmacol. 2024 Jan 21;154:107278. doi: 10.1016/j.vph.2024.107278. Online ahead of print.ABSTRACTAortic aneurysm (AA) and dissection (AD) are aortic diseases caused primarily by medial layer degeneration and perivascular inflammation. They are lethal when the rupture happens. Vascular smooth muscle cells (SMCs) play critical roles in the pathogenesis of medial degeneration, characterized by SMC loss and elastin fiber degradation. Many molecular pathways, including cyclic nucleotide signaling, have been reported in regulating vascular SMC functions, matrix remodeling, and vascular structure integrity. Intracellular c...
Source: Vascular Pharmacology - January 23, 2024 Category: Drugs & Pharmacology Authors: Ting Shu Yitian Zhou Chen Yan Source Type: research
Angiogenesis is promoted by hypoxic cervical carcinoma-derived extracellular vesicles depending on the endothelial cell environment
CONCLUSION: Hypoxia differentially affects CA-EVs in a cell line-dependent manner. The cellular environment (nutrient availability and extracellular matrix scaffold) influences the effect of CA-EV on the angiogenic potential of ECs.PMID:38242295 | DOI:10.1016/j.vph.2024.107276 (Source: Vascular Pharmacology)
Source: Vascular Pharmacology - January 19, 2024 Category: Drugs & Pharmacology Authors: E Orozco-Garc ía V Getova J C Calder ón M C Harmsen R Narvaez-Sanchez Source Type: research
The peripheral corticotropin releasing factor family's role in vasculitis
Vascul Pharmacol. 2024 Jan 4;154:107275. doi: 10.1016/j.vph.2023.107275. Online ahead of print.ABSTRACTCorticotropin releasing factor family peptides (CRF peptides) include 4 members, corticotropin releasing hormone (CRH), Urocortin (UCN1), UCN2 and UCN3. CRF peptides function via the two distinct receptors, CRF1 and CRF2. Among them, CRH/CRF1 has been recognized to influence immunity/inflammation peripherally. Both pro- and anti-inflammatory effects of CRH are reported. Likewise, UCNs, peripherally in cardiovascular system have been documented to have both potent protective and harmful effects, with UCN1 acting on both CR...
Source: Vascular Pharmacology - January 6, 2024 Category: Drugs & Pharmacology Authors: Chao Zhu Shengnan Li Source Type: research
The peripheral corticotropin releasing factor family's role in vasculitis
Vascul Pharmacol. 2024 Jan 4:107275. doi: 10.1016/j.vph.2023.107275. Online ahead of print.ABSTRACTCorticotropin releasing factor family peptides (CRF peptides) include 4 members, corticotropin releasing hormone (CRH), Urocortin (UCN1), UCN2 and UCN3. CRF peptides function via the two distinct receptors, CRF1 and CRF2. Among them, CRH/CRF1 has been recognized to influence immunity/inflammation peripherally. Both pro- and anti-inflammatory effects of CRH are reported. Likewise, UCNs, peripherally in cardiovascular system have been documented to have both potent protective and harmful effects, with UCN1 acting on both CRF1 &...
Source: Vascular Pharmacology - January 6, 2024 Category: Drugs & Pharmacology Authors: Chao Zhu Shengnan Li Source Type: research
The peripheral corticotropin releasing factor family's role in vasculitis
Vascul Pharmacol. 2024 Jan 4:107275. doi: 10.1016/j.vph.2023.107275. Online ahead of print.ABSTRACTCorticotropin releasing factor family peptides (CRF peptides) include 4 members, corticotropin releasing hormone (CRH), Urocortin (UCN1), UCN2 and UCN3. CRF peptides function via the two distinct receptors, CRF1 and CRF2. Among them, CRH/CRF1 has been recognized to influence immunity/inflammation peripherally. Both pro- and anti-inflammatory effects of CRH are reported. Likewise, UCNs, peripherally in cardiovascular system have been documented to have both potent protective and harmful effects, with UCN1 acting on both CRF1 &...
Source: Vascular Pharmacology - January 6, 2024 Category: Drugs & Pharmacology Authors: Chao Zhu Shengnan Li Source Type: research
A treatment algorithm for ischemic cardiomyopathy
Vascul Pharmacol. 2024 Jan 3;154:107274. doi: 10.1016/j.vph.2023.107274. Online ahead of print.ABSTRACTTreatment of ischemic cardiomyopathy has been the focus of increased attention by cardiologists due to recent evidence of an important outcome study comparing percutaneous coronary intervention (PCI) plus optimal medical treatment vs optimal medical treatment alone, concluding for the futility of myocardial revascularization by PCI. A relatively older trial of coronary artery bypass grafting (CABG) in the same condition, on the other hand, had concluded for some prognostic improvement at a long-term follow-up. This short ...
Source: Vascular Pharmacology - January 5, 2024 Category: Drugs & Pharmacology Authors: Raffaele De Caterina Riccardo Liga Source Type: research
Myocardial energy balance and metabolism as causes of myocardial ischemia
Vascul Pharmacol. 2024 Jan 3:107273. doi: 10.1016/j.vph.2023.107273. Online ahead of print.ABSTRACTThe current approach to myocardial ischemia has been influenced by the misconception of a close link between ischemia and coronary atherosclerotic obstructions. Recent guidelines have, however, acknowledged the multifactorial nature of this condition, with an identifiable cause present in less than half of angina patients, and a large fraction with angina of unknown origin. Because of this background, focusing on cardiac energy metabolim offers new opportunities to manage myocardial ischemia even when its cause is unknown.PMI...
Source: Vascular Pharmacology - January 5, 2024 Category: Drugs & Pharmacology Authors: Mario Marzilli Source Type: research
Myocardial energy balance and metabolism as causes of myocardial ischemia
Vascul Pharmacol. 2024 Jan 3:107273. doi: 10.1016/j.vph.2023.107273. Online ahead of print.ABSTRACTThe current approach to myocardial ischemia has been influenced by the misconception of a close link between ischemia and coronary atherosclerotic obstructions. Recent guidelines have, however, acknowledged the multifactorial nature of this condition, with an identifiable cause present in less than half of angina patients, and a large fraction with angina of unknown origin. Because of this background, focusing on cardiac energy metabolim offers new opportunities to manage myocardial ischemia even when its cause is unknown.PMI...
Source: Vascular Pharmacology - January 5, 2024 Category: Drugs & Pharmacology Authors: Mario Marzilli Source Type: research
